Irritable Bowel Syndrome Clinical Trial
Official title:
Use of the Stress Management and Resilience Training (SMART) Program in the Management of Irritable Bowel Syndrome: A Pilot Study
Verified date | May 2020 |
Source | University of California, Los Angeles |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a pilot study to determine the efficacy of the Stress Management and Resilience Training (SMART) program in improving gastrointestinal and psychological symptoms, health-related quality of life, and satisfaction of care in patients with irritable bowel syndrome (IBS). Half of the participants will be enrolled in the SMART program initially. The other half will be placed in a self-management stress reduction program where they will read a popular stress reduction book over 12 weeks. Then they will have access to participate in the online SMART program.
Status | Completed |
Enrollment | 39 |
Est. completion date | February 2, 2020 |
Est. primary completion date | November 7, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Those with a diagnosis of IBS based on the Rome IV diagnostic criteria (recurrent abdominal pain at least once per week in the last 3 months associated with 2 of the following: related to defecation, associated with a change in stool frequency, associated with a change in stool form. Symptoms must have started 6 months prior to presentation) - Between the ages of 18 and 70 - English speaking - Are able to provide written, informed consent - At least moderate IBS symptoms (based on an IBS symptom severity scale score [IBS-SSS] of 175 or higher) - At least moderate levels of perceived stress (based on a perceived stress score of 14 or higher - If receiving pharmacologic therapy for IBS, they must be on a stable dose for 30 days prior to enrollment Exclusion Criteria: - History of gastrointestinal disease including celiac disease, cirrhosis, gastrointestinal malignancy, inflammatory bowel disease - History of gastrointestinal surgery (except appendectomy and cholecystectomy or gallbladder removal >6 months ago) - Poorly controlled psychiatric disease such as severe depression (with or without suicidal ideation), severe anxiety, schizophrenia, dementia - Currently receiving, or have received in the last 6 months, other stress reduction therapies such as mindfulness based stress reduction, meditation - Excessive alcohol intake (up to 1 drink per day for females and 2 drinks per day for males) - Illicit substance use - High dose opiate use - Pregnancy - Non-English speaking - Inability to provide written informed consent |
Country | Name | City | State |
---|---|---|---|
United States | UCLA | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Los Angeles |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in perceived stress score from baseline | Validated questionnaire with 10 questions regarding respondents stress levels | Week 12 (end of the SMART program) | |
Secondary | Change in perceived stress score from baseline | Validated questionnaire with 10 questions regarding respondents stress levels | Week 4 | |
Secondary | IBS symptom severity responder rate | IBS symptom severity will be measured using the validated IBS symptom severity score. A participant will be consider a responder if they have a 50 point reduction in their baseline score. | Week 4, week 12 | |
Secondary | IBS related quality of life responder rate | IBS related quality of life will be measure using a validated questionnaire. A participant is considered a responder if there is a 14 point improvement in their baseline score | Week 4, week 12 | |
Secondary | Change from baseline in resilience scores as measured by the Brief Resilience scale | The Brief Resilience scale is a 6 question validated questionnaire | Week 4, week 12 | |
Secondary | Change from baseline in resilience score as measured by the Connor-Davidson Resilience Scale | The Connor-Davidson Resilience Scale is a 25 question validated questionnaire | Week 4, week 12 | |
Secondary | Change from baseline in adaptive resilience score | A validated questionnaire to measure adaptive resilience will be used | Week 4, week 12 | |
Secondary | Change in gratitude scores from baseline | Gratitude will be measured using a validated questionnaire. | Week 4, week 12 | |
Secondary | Change in mindfulness scores from baseline | Mindfulness will be measured using the validated five factor mindfulness questionnaire | Week 4, week 12 | |
Secondary | Change in patient satisfaction from baseline | The measurement of patient satisfaction will be adapted from the patient global satisfaction scale from the Hospital Consumer Assessment of Healthcare Providers and Systems. | Week 4, week 12 | |
Secondary | Change in anxiety symptoms from baseline | Anxiety symptoms will be measured using the validated hospital anxiety and depression questionnaire | Week 4, week 12 | |
Secondary | Change in gastrointestinal symptom related anxiety from baseline | Gastrointestinal symptom related anxiety will be measured using the validated visceral sensitivity index | Week 4, week 12 | |
Secondary | Change in somatic symptom severity from baseline | Somatic symptom severity will be measured using the validated patient health questionnaire | Week 4, week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A | |
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 |